Day 3 : yet another IgA trial, and we are back with some flozin news: in ADPKD, their effect on hemoglobin, and on BP (with finerenone)
Kidney Week in Denver: Day 2
Kidney Week in Denver: Day 1
NephJC Short: 24-Month Iptacopan eGFR Data in IgA Nephropathy
NephJC Short: When BAFF Meets APRIL: Telitacicept in IgA Nephropathy (TELIGAN trial)
Can we predict who benefits from steroids in IgAN? The PRED-IgAN Study
NephJC Covers LBCTs at the World Congress
ORIGIN 3 interim-story: atacicept in IgAN
Check out ORIGIN 3 recap: a 36-week, interim analysis of phase 3 trial of atacicept in IgAN! Thread by NephJC intern Marc Soco.
Attacking the Origin of IgAN: ORIGIN3 and Atacicept
ORIGIN-3: The Visual Abstract
ORIGIN-3: El Resumen Visual
ORIGIN-3 ha llegado a NephJC con atacicept en NIgA.
Un paso sólido hacia una terapia dirigida anti BAFF/APRIL, que aborda la fisiopatología desde su origen. ¡Las señales tempranas son prometedoras!
Revisa el resumen visual realizado por Clemens Weber
Kidney Week in Houston: Day 1
2025 IgAN KDIGO guidelines: fresh out of press, already aging gracefully
KDIGO 2025 IgA guidelines - Visual Abstract
KDIGO 2025 is here. IgAN management is evolving with precision risk tools, new therapies, and a stronger focus on kidney protection.
Check out the visual abstract created by Natalia Nombera
Guías KDIGO 2025 IgA - El Resumen Visual
Las guías KDIGO 2025 están aquí. El manejo de la nefropatía por IgA (NIgA) está evolucionando con herramientas de estratificación de riesgo más precisas, nuevas terapias y un enfoque más sólido en la protección renal a lo largo de la vida.
Revisa el resumen visual creado por Natalia Nombera
Healing, Hype, or Harm: The NefIgArd trial
The NeflgArd Part B Visual Abstract
Does targeted-release formulation of Budesonide improve kidney function in primary IgA Nephropathy? Check out the VA by NSMC Intern Anant Pilawan on NefIgArd part B trial
🤔 GWAS in IgA Nephropathy
Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy (Kiryluk, Nature Genetics 2023)
🤔 Sibeprenlimab in IgA Nephropathy
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy (Mathur, NEJM 2024)
